US Patent Issued to Iovance Biotherapeutics on Feb. 10 for "Identification of clonal neoantigens and uses thereof" (British Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,548,651, issued on Feb. 10, was assigned to Iovance Biotherapeutics Inc. (San Carlos, Calif.).

"Identification of clonal neoantigens and uses thereof" was invented by Andrew Roth (Oxford, Great Britain), Maximilian Prinz Zu Salm-Horstmar (London) and Fong Chun Chan (London).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of treating a subject having been diagnosed as having cancer with an immunotherapy is described. The method comprises targeting one or more clonal neoantigens selected using a method comprising determining whether a tumour-specific mutation is likely to be clonal in a subject. The method comprises providing sequence data from one...